Anrs, Emerging Infectious Diseases
Clinical trials sponsored by Anrs, Emerging Infectious Diseases, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a drug cocktail slash deaths from TB of the brain? Results expected Sep 2026 (estimated)
- Can a pill speed up monkeypox recovery? major trial underway Results expected Sep 2026 (estimated)
- Exercise program aims to keep HIV patients over 50 on their feet Results expected Oct 2026 (estimated)
- New nasal spray COVID-19 booster could replace needles Results expected Oct 2026 (estimated)
- New vaccine booster aims to shield against many coronaviruses Results expected Oct 2026 (estimated)
-
Liver transplants for HIV-HCV patients: a feasibility study
Disease control Stopped earlyThis study aimed to see if liver transplantation is possible and safe for people infected with both HIV and hepatitis C. Fifteen patients were enrolled to track survival, virus behavior, and drug interactions after transplant. The goal was to understand how these two viruses inte…
Phase 2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
HIV drug showdown: which strategy works best for new patients?
Disease control Stopped earlyThis study compared two HIV treatment approaches in people who had never taken HIV drugs before. One group started with a three-drug combo for 16 weeks, then switched to a two-drug combo. The other group took a two-drug combo from the start. The goal was to see if the first appro…
Phase 3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
HIV pill combo fails to slim belly fat in early trial
Disease control Stopped earlyThis study tested whether switching to a two-drug HIV treatment (raltegravir plus maraviroc) could reduce belly fat (lipohypertrophy) in people whose HIV was already well-controlled. It included 48 adults on stable HIV therapy for at least 5 years. The study was stopped early, so…
Phase 2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC